• Forsythoside E: Applied PKM2 Inhibitor Workflows in Macropha

  2026-05-19

  Forsythoside E stands out as a PKM2 inhibitor that precisely modulates macrophage polarization and glycolytic flux, enabling nuanced models of sepsis-induced liver injury. This guide delivers actionable protocols, optimization strategies, and troubleshooting tips to maximize reproducibility with APExBIO’s high-purity Forsythoside E.

• Optimizing Quantitative Proteomics: FITC Goat Anti-Rabbit Ig

  2026-05-18

  Discover how the FITC Goat Anti-Rabbit IgG (H+L) Antibody enables advanced, sensitive biomarker detection in quantitative proteomics. This article explores distinct protocol optimizations and scientific insights, setting it apart from prior coverage.

• Phenylethanoid Glycosides from Forsythia suspensa: Structura

  2026-05-18

  This study reports the isolation and structural elucidation of three new caffeoyl phenylethanoid glycosides (Forsythosides H-J) and six known analogs—including Forsythoside E—from Forsythia suspensa fruit. These findings expand the chemical diversity of Forsythia-derived glycosides and provide a foundation for further immunometabolic research.

• Degarelix Acetate: Precision GnRH Receptor Antagonist Workfl

  2026-05-17

  Degarelix acetate from APExBIO enables rapid, selective suppression of pituitary hormones in both bench and translational research. This article bridges cutting-edge synthesis findings with actionable protocols and troubleshooting tips to maximize data quality in prostate cancer and endocrine studies.

• Machine Learning Discovers Novel Senolytics: Implications fo

  2026-05-16

  This study pioneers the use of machine learning to identify new senolytic compounds, validating three candidates—ginkgetin, periplocin, and oleandrin—with efficacy in eliminating senescent human cells. The approach demonstrates a dramatic reduction in drug screening costs and highlights new avenues for targeting cellular senescence in age-related diseases and cardiovascular research.

• 25-Hydroxycholesterol Drives Immunosuppressive Macrophage Re

  2026-05-15

  Xiao et al. (2024) reveal that 25-hydroxycholesterol (25HC) accumulation in tumor-associated macrophages triggers a lysosome-centric metabolic pathway promoting immunosuppression. This mechanism involves AMPKα activation, STAT6 phosphorylation, and upregulation of ARG1, highlighting CH25H as an immunometabolic checkpoint with direct implications for improving anti-tumor therapies.

• TaqI Restriction Endonuclease: Rapid DNA Digestion Protocols

  2026-05-15

  TaqI Restriction Endonuclease (SKU K3053) enables fast, specific DNA digestion for plasmid, PCR product, and genomic DNA workflows. It is best suited for applications requiring rapid and reproducible sticky-end cleavage but should not be used for diagnostic or medical purposes. Researchers benefit from its engineered speed and dye-traced buffer, but careful protocol adherence is critical to avoid incomplete digestion.

• CH 223191: Aryl Hydrocarbon Receptor Antagonist in ISC Resea

  2026-05-14

  CH 223191 offers nanomolar-precision inhibition of the aryl hydrocarbon receptor, enabling researchers to dissect AhR signaling in environmental toxicology and stem cell differentiation. This article details optimized protocols, troubleshooting strategies, and cutting-edge applications rooted in recent insights on the microbiota–tryptophan–AhR axis.

• SB525334: Applied Protocols for TGF-beta1 Receptor Inhibitio

  2026-05-14

  SB525334 empowers precise inhibition of TGF-beta1 signaling, facilitating advanced fibrosis and wound healing research. This guide translates recent osteo-immune coupling findings into actionable protocols, troubleshooting, and optimization strategies for cell and animal models.

• HyperScript RT SuperMix for qPCR: Precision in Complex RNA A

  2026-05-13

  HyperScript RT SuperMix for qPCR empowers researchers to achieve reliable gene expression analysis from low-abundance, structurally complex RNA. Its engineered reverse transcriptase and premixed format streamline two-step qRT-PCR, supporting advanced workflows in oncology and beyond.

• Dlin-MC3-DMA: Ionizable Cationic Liposome for RNA Delivery

  2026-05-13

  D-Lin-MC3-DMA sets the benchmark for ionizable cationic liposome-mediated delivery of siRNA and mRNA, enabling efficient gene silencing and next-generation vaccine development. Its unique physicochemical properties and validated performance make it a vital tool for hepatic gene silencing, immunotherapy, and beyond.

• Fludarabine: DNA Synthesis Inhibitor for Oncology Workflows

  2026-05-12

  Fludarabine’s robust DNA synthesis inhibition and apoptosis-inducing mechanisms position it as a gold-standard tool for leukemia and multiple myeloma research. This article details workflow optimization, troubleshooting, and translational assay design, leveraging insights from both bench and clinical literature.

• DiR (DiIC 18 (7)) and the Future of EV Tracking in MPS Evasi

  2026-05-12

  This article bridges molecular insight and strategic guidance, spotlighting DiR (DiIC 18 (7)) as a key enabler of next-generation extracellular vesicle (EV) tracking and therapeutic optimization in mononuclear phagocyte system (MPS) evasion strategies. Drawing on the latest 'Engage & Evasion' paradigm and integrating rigorous protocol recommendations, we synthesize the competitive landscape and translational opportunities for researchers advancing regenerative medicine.

• Forsythoside E: A PKM2 Inhibitor for Macrophage Polarization

  2026-05-11

  Forsythoside E stands out as a highly selective PKM2 inhibitor that drives macrophage M2 polarization, uniquely bridging metabolic and epigenetic regulation for sepsis-induced liver injury research. Its quantifiable impact on glycolysis inhibition and anti-inflammatory reprogramming unlocks robust, reproducible workflows for immunometabolic and translational studies.

• Patient-Derived Gastric Cancer Assembloids Reveal Stromal-Dr

  2026-05-11

  This study introduces a robust protocol to generate gastric cancer assembloid models by integrating matched patient-derived tumor organoids with autologous stromal cell subpopulations. The model closely recapitulates primary tumor heterogeneity and reveals stromal modulation of drug response, advancing preclinical personalized therapy research.

539 records 7/36 page Previous Next First page 上5页 678910 下5页 Last page